PI 0824

Drug Profile

PI 0824

Alternative Names: Peptide immunotherapy - Peptimmune; PI-0824

Latest Information Update: 19 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peptimmune
  • Class Peptides; Skin disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris

Highest Development Phases

  • No development reported Pemphigus vulgaris

Most Recent Events

  • 13 Dec 2007 Orphan Europe has been acquired by Recordati
  • 15 Nov 2006 Peptimmune and Orphan Europe have entered into an agreement to co-promote and co-develop PI 0824 for Pemphigus vulgaris
  • 31 May 2005 Peptimmune has completed a phase trial in Pemphigus vulgaris in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top